Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07070791 | Combined Upper Extremity Resistance and Aerobic Exercise Training in Patients With Breast Cancer | recruiting | N/A | 40 | Hacettepe UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07277738 | Precision Supplemental Imaging in Women With Dense Breasts(PSID) | recruiting | N/A | 78 | Washington University School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07588425 | Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer(C-BREAST-01) | recruiting | — | 100 | Fatih GURLEROTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07748208 | A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes | not yet recruiting | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT07814365 | PBI for Low-risk Breast Cancer | withdrawn | N/A | 0 | Fudan UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823660 | Cardio-Oncology Rehabilitation in Breast Cancer Patients Undergoing Chemotherapy | recruiting | N/A | 30 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02453620 | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 1 | 57 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03804255 | Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting | withdrawn | — | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04362826 | Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer | recruiting | N/A | 100 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04373655 | AXillary Surgery After NeoAdjuvant Treatment(AXSANA) | recruiting | — | 3,000 | European Breast Cancer Research Association of Surgical TrialistsNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT04993313 | Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study | active not recruiting | N/A | 62 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05076266 | COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation | terminated | — | 14 | Eastern Cooperative Oncology GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05115474 | Study of Screening Brain MRIs in Stage IV Breast Cancer | recruiting | Phase 2 | 170 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05206331 | CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study | completed | Phase 4 | 2,089 | Margarita Louise ZuleyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05378464 | Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer | suspended | Phase 1 | 28 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | active not recruiting | Phase 1 | 190 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT05512364 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)(TREAT ctDNA) | recruiting | Phase 3 | 220 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Sep 15, 2026 | clinicaltrials |
| NCT05559411 | MEthods for LOcalization of Different Types of Breast Lesions(MELODY) | recruiting | — | 7,416 | European Breast Cancer Research Association of Surgical TrialistsNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05739591 | Long-term Safety and Efficacy of GBG Study Participants(ETERNITY) | recruiting | — | 400 | GBG Forschungs GmbHOTHER | 2 | Sep 15, 2026 | clinicaltrials |
| NCT05809752 | A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) | active not recruiting | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05825482 | Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout® | active not recruiting | N/A | 32 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05906407 | COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer(COGNITION) | recruiting | — | 2,000 | German Cancer Research CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06274034 | MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors | terminated | Early Phase 1 | 14 | Mayo ClinicOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06336538 | Abbreviated MBCT for Depression in Older Black or African American Breast Cancer Survivors | active not recruiting | N/A | 23 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06351865 | Feasibility Study to Evaluate the Use of Patient Reported Complications After Digital Consent(PRC) | recruiting | — | 50 | Portsmouth Hospitals NHS TrustOTHER_GOV | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06492616 | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence(ELEGANT) | recruiting | Phase 3 | 4,220 | Stemline Therapeutics, Inc.INDUSTRY | 28 | Sep 15, 2026 | clinicaltrials |
| NCT07009093 | Utility of a Mobile Application for Young Women With Breast Cancer | recruiting | N/A | 120 | Wake Forest University Health SciencesOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07137468 | Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk | active not recruiting | — | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07418060 | Evaluation of the Impact of Pre-habilitation Using Physiotherapy and Mechanical Stimulation on Shoulder Pain and Mobility in Patients Undergoing Breast Reconstruction Using a Latissimus Dorsi Flap(PREHAB KINELGD) | recruiting | N/A | 96 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07429487 | Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer(WATCH AND ACT) | recruiting | N/A | 98 | Centre Antoine LacassagneOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07513311 | A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer(RESTORE) | recruiting | N/A | 75 | Massachusetts General HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07638150 | PRehabilitation Intervention to Modify Eating for Breast Cancer Patients (PRIME)(PRIME) | not yet recruiting | N/A | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07681323 | Timing of ctDNA Testing in Advanced Breast Cancer(TIMING) | recruiting | — | 400 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07686250 | Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery | recruiting | Phase 2 | 37 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07796880 | Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer | recruiting | Phase 2 | 80 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07805538 | Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Therapy | withdrawn | N/A | 0 | Fudan UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07819981 | Prehabilitation for Improving Outcomes in Breast Cancer Patients Undergoing Neoadjuvant Systemic Treatment and Surgery | not yet recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07820124 | Digital Education for Breast Cancer Screening Beliefs and Prevention Behaviors | completed | N/A | 120 | Gümüşhane UniversıtyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07821229 | Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer(MCarb-T) | active not recruiting | N/A | 30 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00099437 | Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.(CONFIRM) | active not recruiting | Phase 3 | 736 | AstraZenecaINDUSTRY | 17 | Sep 14, 2026 | clinicaltrials |
| NCT03077841 | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer | suspended | Phase 2 / Phase 3 | 928 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03359954 | Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer | active not recruiting | Phase 2 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04090567 | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | terminated | Phase 2 | 462 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials